Xenon Pharmaceuticals Inc. (XENE) Stock: Price, Forecast & Analyst Target
Xenon Pharmaceuticals Inc. (XENE) — MoonshotScore 56/100 (Fair band), calculated Oct 4, 2026. Price $38.02 (-2.34%), as of the Oct 2, 2026 trading session; market cap $3.68B. Expected results Nov 2, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 3.95× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 2, 2026
Xenon Pharmaceuticals Inc. · XENE · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Xenon Pharmaceuticals is a clinical-stage biotech company in Burnaby, Canada, developing ion channel modulators for neurological disorders including epilepsy. The central question is whether its lead potassium channel program reaches approval, with cash positioned to fund operations through the decade's end.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Xenon Pharmaceuticals (XENE)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 39.51 · Piotroski F 2
Holding back: soft growth, weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 55 | Fair | |
| 55 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 55 | Fair | |
| 55 | Fair |
The score moved from 55 in the stored Oct 3, 2026 snapshot to 56 in the current publication computed Oct 4, 2026 (+1).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $38.02 |
| Change on the day | -2.34% |
| 52-week range | $36.07–$72.66 |
| Market capitalisation | $3.68B |
| Shares traded on the day | 1.94M |
| Beta (volatility vs the S&P 500) | 0.62 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to expect our first Phase 3 MDD study results in the first half of 2027, and we will narrow that guidance as we get closer to the top line readout.
Ian Mortimer · Statement from
Chronological order, not a duration scale. Periods are stated windows, not exact dates. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Xenon Pharmaceuticals (XENE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 15, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 15, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the XENE film — every key number, told as a short cinematic story
~2 min · open the film
What is Xenon Pharmaceuticals (XENE), and what does it report?
Short answer · as of
Xenon discovers and develops small-molecule drugs targeting ion channels in the central nervous system.
Research dated 2026-09-13.
Xenon discovers and develops small-molecule drugs targeting ion channels in the central nervous system. The lead program is a potassium channel activator in late-stage trials for rare developmental epilepsy, advancing through clinical testing with support from strategic partnerships with larger pharmaceutical firms. Earlier-stage candidates address sodium channel inhibition and calcium channel modulation, expanding the therapeutic scope across multiple neurological conditions. Revenue remains minimal, and operations are entirely funded by cash reserves supplemented by occasional partnership revenues from licensing agreements with collaborators. This funding model depends on successful clinical progression and eventual regulatory approval of the lead candidate to reach commercialization.
What do the latest results show for Xenon Pharmaceuticals (XENE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
Recent results reflected ongoing research and development spending with minimal revenue recognition. Operating cash burn remained steady as the company advances clinical trials. Net loss widened from research expenses, but this is expected for a development-stage biotech without approved products.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $99.22M Jun 30, 2026
- Latest quarter · SG&A
- $23.93M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$123.16M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $99.22M | $23.93M | −$123.16M |
| Mar 31, 2026 | Not available | $88.51M | $23.82M | −$112.33M |
| Dec 31, 2025 | Not available | $87.70M | $22.07M | −$109.77M |
| Sep 30, 2025 | Not available | $77.05M | $19.28M | −$96.34M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $1.67M Aug 6, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | Not available | $1.67M | −$1.1100 | −$1.1400 |
| May 7, 2026 | Not available | $1.36M | −$1.1700 | −$1.1700 |
| Feb 26, 2026 | Not available | −$178,571 | −$1.3100 | −$1.2000 |
| Nov 3, 2025 | Not available | Not available | −$1.1500 | −$1.1600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$111M | -$1.11 (diluted) |
| Q1 FY2026 | $0 | -$102M | -$1.17 (diluted) |
| Q4 FY2025 | $0 | -$105M | -$1.33 (diluted) |
| Q3 FY2025 | $0 | -$91M | -$1.15 (diluted) |
What are the financial strengths and risks for Xenon Pharmaceuticals (XENE)?
Short answer
Cash and short-term investments were $930.69M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$95.39M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and investments position operations to continue into the coming years, with estimated runway extending beyond the current planning horizon into the decade's end. Debt is minimal and does not materially constrain operations. The principal risk is clinical trial failure of the lead potassium channel candidate, which would eliminate the company's primary commercial opportunity and force strategic reassessment or restructuring. Partnership agreements with larger companies provide secondary optionality and potential fallback pathways if the lead program encounters difficulties. The company's financial position offers sufficient time to pursue its development strategy, but the milestone dependency on clinical success remains absolute.
Data-derived red flags
- Negative return on equity (-44.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$95.39M Jun 30, 2026
- Previous quarter · operating cash flow
- −$88.90M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$95.39M | −$280,000 |
| Mar 31, 2026 | −$88.90M | −$130,000 |
| Dec 31, 2025 | −$81.48M | −$320,000 |
| Sep 30, 2025 | −$71.75M | −$280,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Xenon Pharmaceuticals (XENE)?
Short answer · as of
The next earnings report is expected on Nov 2, 2026.
Research dated 2026-09-13.
The critical milestone is Phase III data readout for the lead potassium channel candidate in a major epilepsy indication, expected in the near term. Positive results would validate the ion channel approach and likely attract partnership or acquisition interest from larger pharmaceutical companies. Negative or ambiguous data would create existential pressure on the company's valuation and force strategic reassessment of the development portfolio. The Phase III program represents a make-or-break moment, as earlier-stage candidates, while scientifically interesting, lack the commercial immediacy required to support near-term cash needs. Management has guided that sufficient cash exists to fund operations into the decade's end, contingent on rational decision-making regarding the lead program's trajectory.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
The timing and results of those filings and our interactions with regulators, our ability to successfully obtain regulatory approvals, anticipated timing of top line data readouts for our clinical trials of Azetukalner and other candidates and our expectation that we will have sufficient cash to fund operations into 2029.
Colleen Alabiso ·
We continue to expect our first Phase 3 MDD study results in the first half of 2027, and we will narrow that guidance as we get closer to the top line readout.
Ian Mortimer ·
How does Xenon Pharmaceuticals compare with its peers?
Short answer
Xenon Pharmaceuticals's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Ion channel therapeutics for neurology remain scientifically validated and medically important. Xenon's portfolio spans multiple channels and indications, reducing dependence on any single drug. However, the company lacks development and commercialization scale versus larger biotech competitors with approved products and established patient networks.
| Company | Price | Market value | Score |
|---|---|---|---|
| $45.81 Oct 2, 2026 | $3.66B | 96 5-pillar Oct 4, 2026 | |
| $25.16 Oct 2, 2026 | $3.15B | 88 5-pillar Oct 4, 2026 | |
| $19.95 Oct 2, 2026 | $3.42B | 76 5-pillar Oct 4, 2026 | |
| $46.97 Oct 2, 2026 | $3.36B | 74 5-pillar Oct 4, 2026 | |
| $58.51 Oct 2, 2026 | $2.78B | 70 5-pillar Oct 4, 2026 | |
| $84.52 Oct 2, 2026 | $5.10B | 68 5-pillar Oct 4, 2026 | |
| $27.79 Oct 2, 2026 | $3.09B | 66 5-pillar Oct 4, 2026 | |
| $41.40 Oct 2, 2026 | $4.45B | 66 5-pillar Oct 4, 2026 | |
| $116.76 Oct 2, 2026 | $4.88B | 64 5-pillar Oct 4, 2026 | |
| $14.74 Oct 2, 2026 | $5.12B | 62 5-pillar Oct 4, 2026 | |
| Xenon Pharmaceuticals (XENE) — this page | $38.02 | $3.68B | 56 |
| $72.10 Oct 2, 2026 | $3.52B | 50 5-pillar Oct 4, 2026 | |
| $46.81 Oct 2, 2026 | $5.61B | 45 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $46.00 – $90.00
- Consensus target
- $68.63
- Median target
- $67.00
Consensus record · Captured .
Measured against a quoted price of $38.02 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 41
- Identified insiders
- 10
- Purchases
- 2
- Sales
- 5
- Other transactions
- 34
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 325 Period end Jun 30, 2026
- Previous quarter · holders
- 306 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 9,647,998 |
| Blackrock, INC. | 7,522,482 |
| Avoro Capital Advisors LLC | 5,777,777 |
| Polar Capital Holdings PLC | 4,570,556 |
| Driehaus Capital Management LLC | 4,418,557 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
Common Questions About XENE (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
When will the company's key data readouts occur?
The lead potassium channel program in Phase III is expected to generate efficacy data in the near term, representing the primary commercial catalyst for company valuation and strategic options. Earlier-stage candidates targeting sodium inhibition and calcium modulation have scheduled milestone readouts along a staggered timeline, providing value optionality but representing pre-commercial stage development with extended timelines. The Phase III readout in the lead indication is the defining moment for the company's validation thesis and will likely determine the strategic pathway forward, whether toward partnership, acquisition, or continued independent development.
How does partnership with Neurocrine help?
Neurocrine is a neurology-focused biopharma partner with development and commercialization capabilities. The partnership validates the science but commits revenue upside to Neurocrine upon approval.
Could the company run out of cash?
Runway extends several years based on current burn rates and existing cash. However, if clinical trials stall or expansion is needed, external funding would be required, likely at unfavorable terms.
Why is insider selling happening?
Insider transactions are dominated by equity awards and vesting, not strategic selling, consistent with standard biotech practice. No material open-market share sales suggest management confidence in clinical progress.
What is the XENE stock price today?
The last price recorded on this page for Xenon Pharmaceuticals Inc. (XENE) is $38.02, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the XENE price target?
The analyst consensus price target for Xenon Pharmaceuticals Inc. (XENE) is $68.63 (range $46.00 to $90.00, median $67.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (70 figures)
The 70 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Colleen Alabiso (Aug 6, 2026): The timing and results of those filings and our interactions with regulators, our ability to successfully obtain regulatory approvals, anticipated timing of top line data readouts for our clinical trials of Azetukalner and other candidates and our expectation that we will have sufficient cash to fund operations into 2029. Ian Mortimer (Aug 6, 2026): We continue to expect our first Phase 3 MDD study results in the first half of 2027, and we will narrow that guidance as we get closer to the top line readout. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 200 - 3650 Gilmore WAY, Burnaby | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "3650 Gilmore Way, Burnaby, BC, V5G 4W8, CA". |
FMP — 61 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 2, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $38.02 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T18:14:46.248Z. | |
px.change | Change on the day | -2.34% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $3.68B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T18:14:45.128Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.91 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $36.07–$72.66 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 1.94M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.62 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Ian C. Mortimer | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 364 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $18.44M, net result −$78.88M; FY2022 revenue $9.43M, net result −$125.37M; FY2023 revenue $0.00, net result −$182.39M; FY2024 revenue $0.00, net result −$234.33M; FY2025 revenue $7.50M, net result −$345.91M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | License and Service $9.43M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $99.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $23.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$123.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $88.51M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $23.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$112.33M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $87.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $22.07M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$109.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $77.05M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $19.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$96.34M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $1.67M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | −$1.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | −$1.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $1.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.revenue_estimated | Revenue · estimate — report date 2026-02-26 | −$178,571 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_actual | EPS · reported — report date 2026-02-26 | −$1.3100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_estimated | EPS · estimate — report date 2026-02-26 | −$1.2000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | −$1.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | −$1.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $930.69M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$95.39M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $314.41M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $6.42M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.05× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$95.39M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$88.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$280,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$130,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$81.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$320,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$71.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$280,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $46.00 – $90.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $68.63 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $67.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 41 transactions · 2 purchases, 5 sales, 34 other transactions · 10 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 325 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 306 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 9,647,998 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 7,522,482 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Avoro Capital Advisors LLC — shares in provider snapshot | 5,777,777 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Polar Capital Holdings PLC — shares in provider snapshot | 4,570,556 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Driehaus Capital Management LLC — shares in provider snapshot | 4,418,557 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 39.51 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -44.0% · ROA -31.6% · current ratio 21.02 · earnings yield -10.6% · free-cash-flow yield -9.0% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 3.95× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $930.69M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$1.1100) with the recorded estimate (−$1.1400) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 56 of 100 · Fair · pillars 43 / 95 / 52 / 13 / 33 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 55 (stored snapshot Oct 3, 2026) → 56 (current publication computed Oct 4, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-26.revenue_estimated,earn.history.depth.2026-02-26.eps_actual,earn.history.depth.2026-02-26.eps_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Xenon Pharmaceuticals Inc. | 2026-02-26 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-26 |
| SEC filing business address | 200 - 3650 GILMORE WAY, BURNABY The SEC filer business address. Our market-data provider separately lists "3650 Gilmore Way, Burnaby, BC, V5G 4W8, CA". | 2026-09-13 | OFFICIAL | SEC EDGAR filer business address |
| Business description | Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash runway cross-check (ours) | Years: 3.3; Method: cash and short-term investments of $930.7M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($285M per year); Reaches: 2029-10; Cash basis: cash and short-term investments; Cash: $930.70M; Annualized cash use: $285.00M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash, investments and debt | Total debt: $6.42M; Liquidity basis: cash and short-term investments; Total liabilities: $53.38M; Cash and short-term investments: $930.69M; Cash and investments: $1.25B; Long-term investments: $314.41M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-06 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Institutional ownership (13F) | Holders: 325; Quarter: 2026-06-30; Holders previous quarter: 306 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-07 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Revenue by segment | License and Service: $9.43M | 2022-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Insider transactions, last 180 days | Net shares: 62,288; Window days: 180; Price low: $7.38; Clustered days: 2026-06-01; 2026-06-03; Price high: $64.06; Buy transactions: 0; Distinct insiders: 8; Sell transactions: 5; Other transactions: 34; Total transactions: 39; Other transaction types: A-Award: 14, F-InKind: 2, M-Exempt: 18; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-01 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
Data provided for informational purposes only.
ETFs that hold XENE
Funds in our ETF coverage that list XENE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 3.96% |